Sun, Dec 28, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Institutional investors to drive secondary hedge fund market

Tuesday, November 01, 2011
Opalesque Industry Update - Sovereign wealth funds, pension funds and family offices are allocating increasingly large tranches of capital to illiquid hedge funds in the search for high-yielding long-term investment solutions, says Florian de Sigy, CEO and founder of specialist brokerage and advisory firm Gamma Finance.

"Whilst there's a lot of attention being paid to liquid hedge fund strategies, we are also seeing allocations to dedicated portfolios of illiquid hedge funds," says de Sigy. "Over the past 12 months, we have been working with a number of large-scale, long-term investors who have been allocating tranches of $250 million to $500 million to illiquid hedge fund portfolios. Many are now returning for a second tranche at similar levels."

According to de Sigy, this trend has been facilitated by a shift in attitudes to illiquid hedge funds. "In the past, particularly in the immediate post-crisis period, there was a bit of a stigma attached to either owning or running illiquids, but with the realisation that most investors and hedge fund managers have illiquids on their books, this has changed and many investors are looking at this sector as an opportunity."

The current market conditions and regulatory environment are also impacting on the secondary market. "One of the key things we do is help buyers and sellers understand better the real value of an illiquid fund," says Ben Keefe, director of Gamma Finance’s investment advisory business. "Hence, if a bid comes in at a substantial discount, because we have the ability to do a detailed analysis of the fund's holdings, we can give an assessment of whether or not the bid represents good value against what can actually be realised from the underlying assets."

Keefe adds "equally, we are working with investors to identify good long-term buying opportunities. The brokerage business can then help the buyer find a seller."

"Illiquids look attractive for investors who want high yield, and given the low yields available from traditional assets at present, illiquid hedge funds look particularly attractive to investors with a sufficiently long-term investment horizon”, says de Sigy. “They are also a good match for pension funds against long-term liabilities,“

Regulatory changes such as Basel 3 and Solvency 2 are also changing the landscape for the secondary market. “These regulations make it much more expensive for insurance companies and banks to hold illiquid investments on their books because of the increased need for capital adequacy. In many ways this is counter-intuitive as it is often the banks and insurers who need the long-term yield profile that illiquids can offer,” comments de Sigy.

“Its probably too early to be absolutely certain, but based on current trends we can see illiquid hedge funds emerging as an asset class in their own right,” adds de Sigy. “The market is still at a very nascent stage – often the time when the best rewards are to be gained – and traditional measures of activity do not necessarily give a clear view of what is happening underneath – often giving conflicting indicators month on month. Nevertheless, the trend to institutional investors building specialist portfolios of illiquid hedge funds is fairly clear. Current levels of dedicated investment are around the $3 billion mark, and that could easily double in the next year.”

- FG

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its